Eli Lilly and Company News

Recent Verilumia coverage about Eli Lilly and Company (LLY), including reporting-tone insights and market listing information.

• Lilly Reports Retatrutide Trial Results Against Ozempic
• Lilly raises 2026 revenue outlook after 39% sales growth

health

Lilly Reports Retatrutide Trial Results Against Ozempic

Eli Lilly said its experimental drug retatrutide produced greater average weight loss and reduced blood sugar more than Ozempic 2 mg in an 80-week Phase 3 trial involving adults with type 2 diabetes. The company...

Coverage Mix 6 source articles

Left 20% Centre 80% Right 0%

6 days agohealth

markets

Lilly raises 2026 revenue outlook after 39% sales growth

Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% from a year earlier, and raised its full-year revenue forecast to $91 billion to $92 billion as sales volume growth more than offset lower...

Coverage Mix 8 source articles

Left 13% Centre 62% Right 25%

6 days agomarkets